Device Firms Want Their Own Guidelines On Risk Information In Ads
This article was originally published in The Gray Sheet
Executive Summary
FDA's draft guidance on presentation of risk information in advertisements fails to adequately distinguish between devices and drugs, according to device trade group AdvaMed
You may also be interested in...
FDA Plans Public Hearing On Web Advertising For November
FDA will hold a public hearing in November to help guide regulation of Internet and social media promotions for devices, drugs and biologics, the agency announced Sept. 18
FDA Plans Public Hearing On Web Advertising For November
FDA will hold a public hearing in November to help guide regulation of Internet and social media promotions for devices, drugs and biologics, the agency announced Sept. 18
FDA Relies On Cognition Research To Spot Misleading Ads – Draft Guidance
FDA is harnessing established science on human cognition to assess whether a device or drug maker's advertisement is misleading, according to a May 27 draft 1guidance document from the agency